Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$73.17 USD

73.17
8,786,290

-0.09 (-0.12%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $73.13 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Boston Scientific (BSX) Completes First Case With Its PFA System

Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.

Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.

Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands

Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.

Envista (NVST) Q4 Earnings Miss Estimates, Margins Down

Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.

STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.

Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down

Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.

QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands

QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.

Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?

Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Mark Vickery headshot

Top Stock Reports for Eli Lilly, Danaher & Citigroup

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Danaher Corporation (DHR) and Citigroup Inc. (C).

PBH vs. BSX: Which Stock Should Value Investors Buy Now?

PBH vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod

Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

Boston Scientific (BSX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates

Stryker (SYK) delivered earnings and revenue surprises of 5.81% and 3.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Q4 Earnings Due on Jan 31: BSX, TMO & ALGN

Medical Products companies' fourth-quarter results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO and ALGN fare this time.

Boston Scientific (BSX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Boston Scientific (BSX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

The Zacks Analyst Blog Highlights Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific

Microsoft, Procter & Gamble, AstraZeneca, General Electric and Boston Scientific are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Microsoft, Procter & Gamble & AstraZeneca

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Procter & Gamble Company (PG) and AstraZeneca PLC (AZN).

PBH or BSX: Which Is the Better Value Stock Right Now?

PBH vs. BSX: Which Stock Is the Better Value Option?

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.